Announcements
Clarification on news articles
Date of occurrence of the event: Nov 26, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Explanation on news article by Economy Daily News
Date of occurrence of the event: Nov 25, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
1.Date of the event:Nov 25, 2019 2.Time: 14:30:00 NST 3.Location:Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan) 4.Summary: OBI Pharma Inc. to attend …
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
Date of occurrence of the event: Sep 16, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Announcement on change of research and development officer
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Research and development officer …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
Date of occurrence of the event: Aug 31, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not …
Board of Directors Approved the Change of Financial Officer and Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important perational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Financial officer and acting …
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
Date of occurrence of the event: Aug 03, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not …
Announcement on Change of Financial Officer and Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Financial officer and acting …
Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug
Date of occurrence of the event: Jul 29, 2019 Counterparty to the contract or commitment: Tasly Biopharmaceuticals Co. Ltd Relationship to the Company: None Starting and ending dates (or rescission …